This is Mariano Barbacid, a Spanish cancer researcher who recently made the news after finding a cure for an aggressive form of pancreatic cancer in mice. His lab developed a new triple therapy regimen targeting the KRAS cancer pathway, implicated in 90% of pancreatic cancers. The combination of daraxonsib, a RAS(ON) inhibitor, afatinib (EGFR/HER2 inhibitor) and SD36 (a selective STAT3 PROTAC) led to complete elimination of tumour cells over a 200 day study period, bringing much needed hope to this often devastating condition.